Life Science Nation Newsletter | September 20, 2018 | Issue 284

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI Innovation Challenge

  Life Science Investor Mandates  (Sept. 13 - Sept. 19 )
Invests Broadly Across Therapeutics, Devices, Diagnostics, Digital Health, Including Orphan Drugs
Seeks Opportunities in Pre-Revenue, Early-Stage Life Science Technologies with Strong IP
Invests in Therapeutics, Medical Device, and Diagnostic Companies with $585M Fund
Seeks to Invest in Novel, Digital Healthcare Technologies with Strong Incorporation of Data, Including AI, Precision Medicine, etc.
LSN Services
LSN Videos
LSN Media Partners
By Lucy Parkinson, VP of Investor Research, LSN

With RESI returning to NYC on November 5th, investors are flocking to sign up to participate. RESI's unique high-touch partnering and breadth across the four key life science verticals of biotech, medtech, diagnostics, and digital health have attracted an audience of active investors from all over the globe. The ratio of startups to investors at RESI events runs close to 1:1; there's no better opportunity to find the right investor for your life science technology. See below for a selection of the registered investors. We hope you can make it to RESI NYC to meet them.

Confirmed Investors and Strategic Partners 

As of September 20, 2018
By Gregory Mannix, Vice President International Business Development, LSN

LSN holds a high-profile life science competition at every RESI conference - the Innovation Challenge. Thirty early-stage fundraising companies with top-tier life science technologies are selected as finalists to exhibit a poster display of their programs to hundreds of investors and other conference attendees. These companies compete for the exposure and visibility of being named as the top Innovation Challenge company. So you might ask: out of the hundreds of applications we receive, how do we choose the top thirty? The LSN scientific review team has compiled a list of attributes we look for in a company and its IC application.

While the following applies to the Innovation Challenge application itself, the criteria and the tips we provide are also guidelines for companies to use in their fundraising efforts. Much of our evaluation and the questions we ask are based on standard criteria that entrepreneurs will face when speaking with investors.

What are the key elements of a high-scoring company?

The LSN scientific review team uses a detailed rubric with a 200-point scoring system...

By Claire Jeong, Senior Research Analyst, LSN

An increasing number of health systems are seeking to form strategic partnerships with early-stage companies that could serve as a meaningful solution for the various complexities within the healthcare system. These strategic partnerships would be tremendously valuable for a start-up entrepreneur, as the value-add that health system organizations can provide are not limited to direct equity investment. Through working with large health/hospital systems, companies gain access to various channels, abundant resources, and relationships with key clinicians or medical professionals that they otherwise may not be able to manage on their own.

So how can companies seek to access these channels, and what exactly does each organization have to offer? At RESI Boston on September 6th, we had the tremendous pleasure of inviting 5 panelists from health systems - all with a unique approach to working with early-stage innovations - to speak about their work and perspectives in fostering novel innovations that can impact the course of healthcare...

Created & Produced by